Cherian Verghese
Psychiatry · Norristown, PANPI 1104916295
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $231,123 of the $264,298 with a category attached, or 87.4%. Neurocrine Biosciences, Inc. accounts for 74.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $100,551 and has fallen 99.8% since, to $204 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $800.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$196K
- Indivior Inc.$42K
- Sunovion Pharmaceuticals Inc.$13K
- Eisai Inc.$6K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$5K
- Genentech, Inc.$1K
- plus $2K from 8 others
Across 719 payments — averaging $22,299 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7.1M
- Eisai Inc.$4.3M
- Janssen Research & Development, LLC$1.9M
- Sage Therapeutics, LLC$907K
- AbbVie$715K
- Teva Pharmaceuticals USA, Inc.$433K
- plus $651K from 9 others
What the payments were for
- Consulting fees$12,7775%
- Speaking & faculty fees$231,12387%
- Travel & lodging$13,2815%
- Food & beverage$6,9723%
- Education$1300%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 223 | $196,003 |
| Indivior Inc. | 32 | $41,713 |
| Sunovion Pharmaceuticals Inc. | 17 | $12,638 |
| Eisai Inc. | 33 | $5,776 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $4,651 |
| Genentech, Inc. | 2 | $1,022 |
| Otsuka America Pharmaceutical, Inc. | 3 | $987 |
| Avanir Pharmaceuticals, Inc. | 7 | $733 |
| Sage Therapeutics, LLC | 1 | $416 |
| Biogen | 3 | $130 |
| Genentech USA, Inc. | 1 | $92 |
| F. Hoffmann-la Roche AG | 1 | $54 |
| E.r. Squibb & Sons, L.L.C. | 1 | $49 |
| Lilly USA, LLC | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$264,298 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,344 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Norristown
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.